NCT05682859View on ClinicalTrials.gov

Treatment of Chronic Hand Eczema With Oral Roflumilast (HERO)

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 25, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2026

Conditions
Chronic Hand Eczema
Interventions
DRUG

Roflumilast 500 Mcg Oral Tablet

Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.

DRUG

Placebo

Placebo tablets

Trial Locations (1)

2400

RECRUITING

Department of dermatology and veneorology, Bispebjerg Hospital, Copenhagen

All Listed Sponsors
collaborator

The Novo Nordic Foundation

OTHER

lead

Jacob Pontoppidan Thyssen

OTHER